Utility of <sup>18</sup> F-Flotufolastat Positron Emission Tomography/Computed Tomography Imaging in High-Risk Prostate Cancer in a Real-World Setting
PSMA PET/CT with <sup>18</sup>F-flotufolastat led to clinical upstaging in nearly one-third of men with high-risk PCa and negative conventional imaging, resulting in significant treatment change in most patients. These findings support the integration of PSMA-targeted imaging into initial staging pathways for men with high-risk PCa.
Authors
- Laurence Belkoff (ORCID: https://orcid.org/0000-0003-2789-6815)
- Zachariah Taylor (ORCID: https://orcid.org/0000-0003-3277-2278)
- Ilia S. Zeltser
- Nachum Stollman
- Kayla G Meyer
- Cheryl Zinar
Institutions
- Philadelphia College of Osteopathic Medicine (US)
- Main Line Health (US)
- Bryn Mawr Hospital (US)
- Abington Memorial Hospital (US)
Publication Details
- Journal
- Urology Practice
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1097/upj.0000000000000971
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00